AbbVie Halts Another Trial With I-Mab Antibody, Slashes Deal Size

CD47 discontinuation
AbbVie has now terminated two early global trials with I-Mab's lemzoparlimab • Source: Shutterstock

More from Clinical Trials

More from R&D